Advances in Colloid and Interface Science, Год журнала: 2023, Номер 316, С. 102908 - 102908
Опубликована: Апрель 25, 2023
Язык: Английский
Frontiers in Immunology, Год журнала: 2020, Номер 11
Опубликована: Авг. 7, 2020
The use of biomarkers in diagnosis, therapy and prognosis has gained increasing interest over the last decades. In particular, analysis cancer patients within pre- post-therapeutic period is required to identify several types cells, which carry a risk for disease progression subsequent relapse. Cancer stem cells (CSCs) are subpopulation tumor that can drive initiation cause relapses. At time point initiation, CSCs originate from either differentiated or adult tissue resident cells. Due their importance, characterize have been identified correlated prognosis. However, shown display high plasticity, changes phenotypic functional appearance. Such induced by chemo- radiotherapeutics as well senescent alterations microenvironment. Induction senescence causes shrinkage modulating an anti-tumorigenic environment undergo growth arrest immune attracted. Besides these positive effects after therapy, also negative displayed post-therapeutically. These unfavorable directly promote stemness CSC plasticity phenotypes, activating pathways non-CSCs, promoting escape activation pathways. end, all lead relapse metastasis. This review provides overview most frequently used markers implementation focussing on deadliest solid (lung, stomach, liver, breast colorectal cancers) hematological (acute myeloid leukemia, chronic leukemia) cancers. Furthermore, it gives examples how might be influenced therapeutics, such radiotherapy, It points out, crucial monitor residual CSCs, pro-tumorigenic senescence-associated secretory phenotype follow-up using specific biomarkers. As future perspective, targeted immune-mediated strategy chimeric antigen receptor based approaches removal remaining chemotherapy-resistant personalized therapeutic approach discussed.
Язык: Английский
Процитировано
764
Advanced Materials, Год журнала: 2018, Номер 30(29)
Опубликована: Май 28, 2018
Controlled delivery of protein therapeutics remains a challenge. Here, the inclusion diselenide-bond-containing organosilica moieties into framework silica to fabricate biodegradable mesoporous nanoparticles (MSNs) with oxidative and redox dual-responsiveness is reported. These diselenide-bridged MSNs can encapsulate cytotoxic RNase A 8-10 nm internal pores via electrostatic interaction release payload matrix-degradation controlled mechanism upon exposure or conditions. After surface cloaking cancer-cell-derived membrane fragments, these bioinspired A-loaded exhibit homologous targeting immune-invasion characteristics inherited from source cancer cells. The efficient in vitro vivo anti-cancer performance, which includes increased blood circulation time enhanced tumor accumulation along low toxicity, suggests that cell-membrane-coated, dual-responsive degradable represent promising platform for bio-macromolecules such as nucleic acid therapeutics.
Язык: Английский
Процитировано
332
Theranostics, Год журнала: 2019, Номер 9(26), С. 8073 - 8090
Опубликована: Янв. 1, 2019
The use of nanomedicine for cancer treatment takes advantage its preferential accumulation in tumors owing to the enhanced permeability and retention (EPR) effect.The development has promised highly effective options unprecedented by standard therapeutics.However, therapeutic efficacy passively targeted is not always satisfactory because it largely influenced heterogeneity intensity EPR effect exhibited within a tumor, at different stages among individual tumors.In addition, limited data on effectiveness human hinders further clinical translation nanomedicine.This unsatisfactory outcome mice humans necessitates novel approaches improve effect.This review focuses current attempts overcoming limitations traditional EPR-dependent incorporating supplementary strategies, such as additional molecular targeting, physical alteration, or physiological remodeling tumor microenvironment.This will provide valuable insight researchers who seek overcome relying alone go "beyond effect".
Язык: Английский
Процитировано
292
Reactive and Functional Polymers, Год журнала: 2020, Номер 148, С. 104501 - 104501
Опубликована: Янв. 18, 2020
Язык: Английский
Процитировано
279
Biomaterials, Год журнала: 2019, Номер 218, С. 119358 - 119358
Опубликована: Июль 15, 2019
Язык: Английский
Процитировано
235
Microporous and Mesoporous Materials, Год журнала: 2018, Номер 275, С. 152 - 162
Опубликована: Авг. 26, 2018
Язык: Английский
Процитировано
168
Journal of Controlled Release, Год журнала: 2020, Номер 329, С. 676 - 695
Опубликована: Окт. 3, 2020
Язык: Английский
Процитировано
152
Progress in Materials Science, Год журнала: 2023, Номер 139, С. 101167 - 101167
Опубликована: Июль 26, 2023
Язык: Английский
Процитировано
45
Heliyon, Год журнала: 2024, Номер 10(4), С. e26009 - e26009
Опубликована: Фев. 1, 2024
Drug-delivery systems (DDSs) are designed to deliver drugs their specific targets minimize toxic effects and improve susceptibility clearance during targeted transport. Peptides have high affinity, low immunogenicity, simple amino acid composition, adjustable molecular size; therefore, most peptides can be coupled via linkers form peptide-drug conjugates (PDCs) act as active pro-drugs. PDCs widely thought promising DDSs, given ability drug bio-compatibility physiological stability. Peptide-based DDSs often used therapeutic substances such anti-cancer nucleic acid-based drugs, which not only slow the degradation rate of in vivo but also ensure concentration at site prolong half-life vivo.This article provides an profile advancements future development functional peptide-based delivery both domestically internationally recent years, expectation achieving incorporating taking full advantage synergistic effects.
Язык: Английский
Процитировано
19
Bioconjugate Chemistry, Год журнала: 2018, Номер 30(2), С. 305 - 324
Опубликована: Ноя. 14, 2018
Protein/peptide drugs possess unique advantages, such as high pharmacological potency, molecular specificity, multifunctionality, and low toxicity, thus hold great potential for use in cancer therapy. In the past decades, achievements have been made protein delivery systems, which can protect cargo proteins against detrimental physiological environments efficiently deliver into tumor sites cells. this Review, we first summarize existing protein/peptide used treatment, illustrate their anti-tumor mechanisms, point out challenges/barriers medical utility. We then discuss strategies encapsulation/conjugation survey recent advances development of vehicles, including lipid-based membrane nanocarriers, polymeric carriers, metal–organic frameworks, inorganic protein/peptide-based DNA nanostructures. The design strategies, advantages potentiating efficiencies, possible limitations these systems are also discussed. Finally, future opportunities challenges anti-cancer indicated.
Язык: Английский
Процитировано
145